RS59250B1 - Novi solvatni kristalni oblik rifaksimina, njegova proizvodnja, kompozicije i upotreba - Google Patents

Novi solvatni kristalni oblik rifaksimina, njegova proizvodnja, kompozicije i upotreba

Info

Publication number
RS59250B1
RS59250B1 RSP20191133A RS59250B1 RS 59250 B1 RS59250 B1 RS 59250B1 RS P20191133 A RSP20191133 A RS P20191133A RS 59250 B1 RS59250 B1 RS 59250B1
Authority
RS
Serbia
Prior art keywords
rifaximin
compositions
production
crystal form
solvated crystal
Prior art date
Application number
Other languages
English (en)
Inventor
Giuseppe Claudio Viscomi
Paola Maffei
Annalisa Sforzini
Fabrizia Grepioni
Laura Chelazzi
Original Assignee
Alfasigma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma Spa filed Critical Alfasigma Spa
Publication of RS59250B1 publication Critical patent/RS59250B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
RSP20191133 2014-05-12 2015-05-07 Novi solvatni kristalni oblik rifaksimina, njegova proizvodnja, kompozicije i upotreba RS59250B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992017P 2014-05-12 2014-05-12
EP15726344.3A EP3143027B1 (en) 2014-05-12 2015-05-07 New solvated crystal form of rifaximin, production, compositions and uses thereof
PCT/IB2015/053342 WO2015173697A1 (en) 2014-05-12 2015-05-07 New solvated crystal form of rifaximin, production, compositions and uses thereof

Publications (1)

Publication Number Publication Date
RS59250B1 true RS59250B1 (sr) 2019-10-31

Family

ID=53276210

Family Applications (2)

Application Number Title Priority Date Filing Date
RSP20191133 RS59250B1 (sr) 2014-05-12 2015-05-07 Novi solvatni kristalni oblik rifaksimina, njegova proizvodnja, kompozicije i upotreba
RS20200857A RS60576B1 (sr) 2014-05-12 2015-05-07 Priprema i upotreba tau kristalnog oblika rifaksimina solvatisanog sa degme

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20200857A RS60576B1 (sr) 2014-05-12 2015-05-07 Priprema i upotreba tau kristalnog oblika rifaksimina solvatisanog sa degme

Country Status (17)

Country Link
US (2) US9938298B2 (sr)
EP (2) EP3143027B1 (sr)
JP (1) JP6576953B2 (sr)
KR (1) KR102362719B1 (sr)
AU (1) AU2015260837B2 (sr)
CA (1) CA2940601C (sr)
DK (2) DK3143027T3 (sr)
EA (1) EA030457B1 (sr)
ES (2) ES2810010T3 (sr)
HR (2) HRP20191520T1 (sr)
HU (2) HUE044748T2 (sr)
NZ (1) NZ723571A (sr)
PL (2) PL3546464T3 (sr)
PT (2) PT3143027T (sr)
RS (2) RS59250B1 (sr)
SI (2) SI3546464T1 (sr)
WO (1) WO2015173697A1 (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698630B1 (en) 2005-03-03 2014-09-03 ALFA WASSERMANN S.p.A. New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
PL3546464T3 (pl) 2014-05-12 2020-11-02 Alfasigma S.P.A. Sposób wytwarzania i zastosowanie postaci krystalicznej Tau rifaksyminy solwatowanej z DEGME
CA3111353A1 (en) 2018-09-06 2020-03-12 Fachhochschule Nordwestschweiz Controlled drug release formulation
WO2020208140A1 (en) 2019-04-12 2020-10-15 Sandoz Ag Rifaximin-containing granules

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
IT1253711B (it) 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
IT1264494B1 (it) 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
JP4195728B2 (ja) 1996-10-16 2008-12-10 ナポ ファーマシューティカルズ，インコーポレーテッド プロアントシアニジンポリマー止瀉組成物の腸溶製剤
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US20030157174A1 (en) 2000-03-23 2003-08-21 Takayuki Tsukuda Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
DE10045547A1 (de) 2000-09-14 2002-04-04 Infineon Technologies Ag Verfahren zur systemunabhängigen digitalen Erzeugung von Mobilkommunikations-Sendesignalen verschiedener Mobilfunkstandards
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
SE528938C2 (sv) 2005-02-08 2007-03-20 Ortic Ab Hydroformningsenhet
US20060210492A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US8003118B2 (en) 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
EP1698630B1 (en) 2005-03-03 2014-09-03 ALFA WASSERMANN S.p.A. New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
KR101667534B1 (ko) 2006-09-22 2016-10-19 씨아이피엘에이 엘티디. 리팍시민
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
WO2009008005A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
ES2798253T3 (es) 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
WO2009008006A2 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
SG188931A1 (en) 2008-02-25 2013-04-30 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
KR20100122937A (ko) 2008-02-26 2010-11-23 샐릭스 파마슈티컬스 리미티드 장 질환의 치료 방법
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
DK2350096T3 (da) 2008-10-02 2020-03-02 Salix Pharmaceuticals Ltd Fremgangsmåder til behandling af hepatisk encephalopati
WO2010044093A1 (en) 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
KR20110107806A (ko) 2008-12-10 2011-10-04 시플라 리미티드 리팍시민 복합체
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
PL2493471T3 (pl) 2009-10-26 2020-10-19 Borody Nowa skojarzona terapia jelitowa
KR20140015140A (ko) 2009-10-27 2014-02-06 루핀 리미티드 리팍시민의 고형 분산물
WO2011061748A1 (en) 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
WO2011061519A2 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
AU2010320653A1 (en) 2009-11-23 2012-06-21 Cipla Limited Topical foam composition
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
CN101773465B (zh) 2010-01-19 2012-11-07 南京泛太化工医药研究所 以氨基酸为稳定剂的聚合物胶束载药系统
WO2011110930A2 (en) 2010-03-10 2011-09-15 Lupin Limited Rifaximin ready-to-use suspension
JP2013527246A (ja) 2010-06-03 2013-06-27 サリックス ファーマシューティカルズ リミテッド リファキシミンの型およびその使用
WO2011156897A2 (en) 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
MY165086A (en) 2010-07-12 2018-02-28 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
NZ607935A (en) 2010-09-13 2015-01-30 Cipla Ltd Pharmaceutical compositions comprising rifaximin
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
JP6076267B2 (ja) 2011-02-11 2017-02-08 サリックス ファーマスーティカルズ，リミテッド リファキシミンの形態およびその使用
CA2834829A1 (en) * 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
US20140308350A1 (en) 2013-04-12 2014-10-16 Alfa Wassermann S.P.A. Nsaid administration and related compositions, methods and systems
AU2014265248A1 (en) 2013-05-17 2015-11-26 Salix Pharmaceuticals, Inc. Methods of using rifaximin in position emission tomography (PET) scans
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ITMI20131307A1 (it) 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
US9765088B2 (en) 2014-04-19 2017-09-19 Granules India Limited Process for the preparation of rifamycin derivatives
PL3546464T3 (pl) 2014-05-12 2020-11-02 Alfasigma S.P.A. Sposób wytwarzania i zastosowanie postaci krystalicznej Tau rifaksyminy solwatowanej z DEGME
WO2016063289A2 (en) 2014-10-22 2016-04-28 Strides Arcolab Limited Pharmaceutical tablet compositions comprising rifaximin
WO2017021975A1 (en) 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
HUE056045T2 (hu) 2016-03-24 2022-01-28 Sandoz Ag Rifaximin alfa és delta tartalmú gyógyászati készítmény
EP3536311B1 (en) 2016-03-24 2021-12-22 Sandoz AG Storage stable composition comprising rifaximin alpha
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
WO2018158646A1 (en) 2017-03-02 2018-09-07 Granules India Limited Rifaximin crystalline form
WO2018178777A1 (en) 2017-03-31 2018-10-04 Granules India Limited Process for the preparation of rifaximin crystalline form
US11052071B2 (en) 2017-04-26 2021-07-06 Sandoz Ag Oral dosage form comprising rifaximin in form beta

Also Published As

Publication number Publication date
ES2742106T3 (es) 2020-02-13
EA030457B1 (ru) 2018-08-31
EP3546464A1 (en) 2019-10-02
RS60576B1 (sr) 2020-08-31
PL3143027T3 (pl) 2019-11-29
ES2810010T3 (es) 2021-03-08
EP3546464B1 (en) 2020-06-17
HUE050054T2 (hu) 2020-11-30
US20170088557A1 (en) 2017-03-30
CA2940601C (en) 2021-08-24
JP2017515821A (ja) 2017-06-15
SI3546464T1 (sl) 2020-09-30
PL3546464T3 (pl) 2020-11-02
JP6576953B2 (ja) 2019-09-18
US9938298B2 (en) 2018-04-10
EP3143027B1 (en) 2019-07-10
KR102362719B1 (ko) 2022-02-14
SI3143027T1 (sl) 2019-10-30
PT3546464T (pt) 2020-08-05
CA2940601A1 (en) 2015-11-19
AU2015260837B2 (en) 2019-02-28
KR20170003568A (ko) 2017-01-09
AU2015260837A1 (en) 2016-09-15
HRP20201093T1 (hr) 2020-10-30
EP3143027A1 (en) 2017-03-22
EA201692110A1 (ru) 2017-05-31
HRP20191520T1 (hr) 2019-11-29
US10428086B2 (en) 2019-10-01
US20180354971A1 (en) 2018-12-13
NZ723571A (en) 2020-02-28
DK3546464T3 (da) 2020-07-27
DK3143027T3 (da) 2019-08-12
HUE044748T2 (hu) 2019-11-28
WO2015173697A1 (en) 2015-11-19
PT3143027T (pt) 2019-09-20

Similar Documents

Publication Publication Date Title
HK1245326A1 (zh) 用於生產scaav的組合物和方法
HRP20192145T1 (hr) Pripravci nosača-antitijela i metode pripreme i uporabe istih
ZA201604831B (en) Hybridosomes, compositions comprising the same, processes for their production and uses thereof
IL264454A (en) Novel compositions, uses and methods for making them
EP3224012A4 (en) Methods and compositions for concrete production
SI3102555T1 (sl) Sestavki spojin in njihove uporabe
EP3200802A4 (en) Compositions and methods for maintaining cognitive function
IL249872A0 (en) Amorphous form of eliglostat hemetrate, preparations containing it and methods for its preparation
PT3143027T (pt) Nova forma de cristal solvatado de rifaximina, produção, composições e utilização dos mesmos
PL2998311T3 (pl) Mieszanina alkiloglikozydów, ich wytwarzanie i zastosowanie
EP3136864A4 (en) Compositions, methods of making a composition, and methods of use
EP3141543A4 (en) New vortioxetine intermediate and synthesis process thereof
GB201509023D0 (en) Compositions and methods of production thereof
EP3109243A4 (en) GAMMA BUTYLOLACTONE COMPOSITION AND METHOD OF PREPARING THEREOF
SG11201605176UA (en) Production engineering networks
AU2014901633A0 (en) Compositions and methods of production and use thereof
GB201509277D0 (en) Production of 3-alkylphenols and uses thereof
GB201417601D0 (en) Articles of manufacture
AU2014902893A0 (en) Probiotic composition, methods of production and methods of use
GB201412053D0 (en) Articles of manufacture